Plant-Based Biologics With iBio's Randy Maddux
iBio COO Randy Maddux walks us through the Bryan, Texas-based biopharma's attempt to turn the CHO cell biologic development paradigm on its ear with hydroponically-grown N. benthamiana. His company's FastPharming approach to protein production, he says, could be modularized to speed cycle times and dramatically reduce upstream costs at scales large and small. For its part, iBio is proving out the approach on a host of therapeutic and vaccine candidates for oncological, infectious, and fibrotic diseases.
Learn more about iBio's COVID-19 vaccine candidate from CEO Tom Isett and Head of Vaccine Development Melissa Berquist, Ph.D. in this feature story at bioprocessonline.com.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.